Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strides Pharma ScienceNSE:STAR -0.27%68 5-Year Yield-on-Cost % is 0.37 as of Jul. 15, 2026, which is 58% below its 10-year median of 0.88. GuruFocus rates NSE:STAR with a GF Score™ of 68/100 and a GF Value™ of ₹780.73 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 515 Drug Manufacturers companies, Strides Pharma Science ranks worse than 87.38% on this metric.
Strides Pharma Science's yield on cost for the quarter that ended in Mar. 2026 was 0.37.
The historical rank and industry rank for Strides Pharma Science's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:STAR'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.23 Med: 0.88 Max: 10.72
Current: 0.37
During the past 13 years, Strides Pharma Science's highest Yield on Cost was 10.72. The lowest was 0.23. And the median was 0.88.
NSE:STAR's 5-Year Yield-on-Cost % is ranked worse than 87.38% of 515
companies
in the Drug Manufacturers industry
Industry Median: 2.25
vs NSE:STAR: 0.37
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Strides Pharma Science 5-Year Yield-on-Cost % Related Terms
NSE:STAR vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Strides Pharma Science (NSE:STAR) has a 5-Year Yield-on-Cost % of 0.37 as of Jul. 15, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Strides Pharma Science and its competitors. This is 58% below median its historical median of 0.88. Over the past decade, Strides Pharma Science's 5-Year Yield-on-Cost % has ranged from 0.23 to 10.72. According to the industry distribution chart, Strides Pharma Science ranks #450 out of 515 companies in the Drug Manufacturers industry, placing it in the top 87.4%.
Is Strides Pharma Science's 5-Year Yield-on-Cost % too high?
Strides Pharma Science's current 5-Year Yield-on-Cost % of 0.37 is 58% below median its 10-year median of 0.88. Over the past 10 years, this metric has ranged from a low of 0.23 to a high of 10.72. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.25. Strides Pharma Science's value of 0.37 is 83.6% below this industry median. Based on the distribution chart, Strides Pharma Science ranks #450 out of 515 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Strides Pharma Science has a GF Score™ of 68/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Strides Pharma Science ranks #450 out of 515 companies for 5-Year Yield-on-Cost %. This places Strides Pharma Science in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.25. Strides Pharma Science's value of 0.37 is 83.6% below this benchmark. Historically, Strides Pharma Science's own 5-Year Yield-on-Cost % has ranged from 0.23 to 10.72 over the past decade. While the company's 10-year median is 0.88 vs. the industry median of 2.25, Strides Pharma Science has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.25, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strides Pharma Science's current 5-Year Yield-on-Cost % of 0.37 is 83.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Strides Pharma Science and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strides Pharma Science's current 5-Year Yield-on-Cost % is 0.37, which is 58% below median its own 10-year median of 0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹780.73, compared to a current price of ₹1,071.10 — trading 37.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.37, which is 58% below median its 10-year median of 0.88 and 83.6% below the Drug Manufacturers industry median of 2.25. Strides Pharma Science's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current 5-Year Yield-on-Cost % is 0.37 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,071.10 is trading 37.2% above its estimated GF Value™ of ₹780.73.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
5-Year Yield-on-Cost %: 0.37 (58% below median its 10-year median of 0.88)
GF Value™: ₹780.73 vs. price of ₹1,071.10 (37.2% above fair value)
Industry Position: 83.6% below the Drug Manufacturers median (#450 of 515)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
68GF Score
Get the complete analysis for NSE:STAR
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
